Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Claude Cormier who wrote (8369)	1/7/2002 5:31:43 PM
From: Mark Bartlett	Respond to of 14101

Claude, I am not sure about the phase II but the phase III had a few hundred. In addition H/C allowed DMX to do a phase IV that involved about 3000 patients and over 100 doctors. MB

To: Claude Cormier who wrote (8369)	1/7/2002 8:41:16 PM
From: Cal Gary	Read Replies (2) \| Respond to of 14101

Hi Claude This is all I have: Phase III (2) Canada double blinded 194 2-Oct-00 Phase IV Canada unblined 3500 Dec-99 There were 2 Phase III clinicals done for Pennsaid. The first was submitted to both FDA and HC. HC requested a more up to date second phase III which DMX happened to have in their back pockets at the time. This second double blined Phase III enrolled 194 patients and used the WOMAC standard. News Released Oct 2, 2000. It is believed that the FDA did not require the second Phase III. There is debate whether the second Phase III was forwarded anyways to the FDA. Hope this helps. I'd be interested in filling in the blanks in my worksheet. DMX: A company with 2 Phase III drug products